QIAGEN announces plans for transition in leadership of Supervisory Board

• Supervisory Board intends to elect Stephen H. Rusckowski as Chairman following Annual General Meeting on June 26, 2025

• Lawrence A. Rosen will not stand for re-election and will step down as Chairman and Supervisory Board member following Annual General Meeting on June 26, 2025

• Prof. Dr. Elaine Mardis will also not stand for re-election after serving since 2014

• All other current Supervisory Board members will stand for re-election to one-year terms

VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to succeed Lawrence A. Rosen as Chairman of the Supervisory Board following its Annual General Meeting on June 26, 2025.

The change comes after Mr. Rosen has decided to step down as Chairman of the Supervisory Board and as a Supervisory Board member upon completion of the Annual General Meeting. Mr. Rosen has served on the Supervisory Board since 2013 and has held the role of Chairman since August 2020.

Mr. Rusckowski joined the Supervisory Board in 2023 and currently serves as Chair of the Nomination & Governance Committee. He is a recognized international healthcare industry leader and most recently served as Chairman, President and CEO of Quest Diagnostics and previously as CEO of Philips Healthcare.

“I am honored to take on this role and support the next phase of QIAGEN’s growth. I deeply believe in our mission and in QIAGEN’s ability to deliver critical molecular insights that advance science and improve healthcare. From basic academic research to clinical healthcare, our solutions are making a difference – and so are our QIAGENers. I want to thank Larry for his steady and thoughtful leadership and look forward to working with my fellow Board members to guide QIAGEN’s future and enhance value for the company’s shareholders and other stakeholders,” Mr. Rusckowski said.

Mr. Rosen said: “QIAGEN is an exceptional company, and it has been a privilege to serve on the Supervisory Board during a period of transformational growth. Over these years, we have supported a focused growth strategy and strengthened our governance. I am especially proud of the evolution of the Supervisory Board, with five new members joining since 2020 who have brought fresh perspectives, deep expertise and proven leadership to complement its already strong profile. I want to thank my colleagues on the Supervisory Board, the leadership team and all QIAGENers for their collaboration and commitment.”

Additionally, Prof. Dr. Elaine Mardis has also decided not to stand for re-election to the Supervisory Board. QIAGEN would like to thank Dr. Mardis for her many contributions during her service on the Supervisory Board since 2014 and as key member of the Science & Technology Committee.

All other current members of the Supervisory Board – Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert Van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, and Ms. Elizabeth Tallett – will stand for re-election to serve one-year terms.

Following the AGM, the Supervisory Board will consist of eight members, reflecting the implementation of a plan announced in 2024 to streamline its size and return to a composition consistent with historical levels.

For more information about QIAGEN’s Supervisory Board, please visit https://www.qiagen.com/us/leadership/supervisory-board

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the “Risk Factors” contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507719506/en/

Investor Relations

John Gilardi, +49 2103 29 11711

Domenica Martorana, +49 2103 29 11244

e-mail: ir@QIAGEN.com

Public Relations

Thomas Theuringer, +49 2103 29 11826

e-mail: pr@QIAGEN.com

Source: QIAGEN N.V.